Felimazole label

Felimazole

Felimazole Recall

Get an alert when a recall is issued.

Add Info

Side Effects & Adverse Reactions

Methimazole has anti-vitamin K activity and may induce bleeding diathesis without evidence of thrombocytopenia. See ADVERSE REACTIONS.

Add Info

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Add Info

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

Add Info

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Add Info

Uses

FELIMAZOLE (methimazole) Coated Tablets are indicated for the treatment of hyperthyroidism in cats.

Add Info

History

There is currently no drug history available for this drug.

Add Info

Other Information

Methimazole is a thioureylene antithyroid drug, which inhibits the synthesis of thyroid hormones. Methimazole (1-methylimidazole-2-thiol) is a white, crystalline substance that is freely soluble in water. The chemical formula is C4H6N2S. Molecular weight is 114.16.

Methimazole Chemical Structure

Chemical Structure

Add Info
Add to My Alerts
Report Side Effect
Leave a Review
Navigate to :
Felimazole Recall
Side Effects & Adverse Reactions
Legal Issues
FDA Safety Alerts
Manufacturer Warnings
FDA Labeling Changes
Uses
History
Other Information
Manufacturers
Trending Topics

Felimazole Manufacturers

  • Dechra Veterinary Products
    Felimazole | Dechra Veterinary Products
    No Recall

    Felimazole | Dechra Veterinary Products

    Felimazole | Dechra Veterinary Products

    The starting dose of FELIMAZOLE Coated Tablets is 2.5 mg administered every 12 hours. Following 3 weeks of treatment, the dose should be titrated to effect based on individual serum total T4 (TT4) levels and clinical response. Dose adjustments should be made in 2.5 mg increments. The maximum total dosage is 20 mg per day divided, not to exceed 10 mg as a single administration.

    Hematology, biochemistry, and TT4 should be evaluated prior to initiating treatment and monitored after 3 weeks and 6 weeks of treatment. Thereafter, bloodwork should be monitored every 3 months and the dose adjusted as necessary. Cats receiving doses greater than 10 mg per day should be monitored more frequently.

Login To Your Free Account